Research · Sep 3, 2026
[KVUE] Kenvue Thesis 2026: Brand Stabilization + Tylenol/Listerine Recovery + Starboard Activist Engagement Test Post-J&J Spin Operational Reset
Kenvue FY2025 revenue ~$15.5-16B (+1-3%) with adj. EPS ~$1.10-1.20 reflecting continued post-spin operational challenges with selected brand category share losses (Tylenol + Listerine + selected facing competitive intensity from store-brand + selected) partially offset by selected operational improvements + Self Care segment recovery + selected pricing. Consumer health products company spun off from Johnson & Johnson August 2023 (IPO May 2023 $3.8B at $22/share + tax-free distribution August 2023; J&J shareholders received 1.5306 KVUE shares per JNJ share). 3 segments: Self Care ~$8B (~50% — Tylenol + Motrin + Sudafed + Zyrtec + Benadryl + Imodium + Pepcid), Skin Health & Beauty ~$4B (~25% — Neutrogena + Aveeno + Clean & Clear), Essential Health ~$3-4B (~25% — Listerine + Band-Aid + Johnson's Baby). CEO Thibaut Mongon since 2023 (Kenvue's first independent CEO; ex-J&J Consumer Health President 2018-2023; French-American executive; ~25-year J&J career). Multiple iconic brands experienced selected share losses post-spin (2023-2025) reflecting spin-off operational disruption + reduced J&J corporate marketing budget allocation + selected consumer trade-down to store-brands. Starboard Value disclosed ~$1B+ Kenvue position 2024-2025 with portfolio rationalization + capital return acceleration thesis; selected board engagement + selected strategic review ongoing. Tylenol multi-decade product liability litigation continuing post-spin (selected indemnification arrangements). Capital return: dividend $0.83-0.84/share + buybacks $1B; net debt $8-9B; Baa1/BBB+ investment grade. FY2026 thesis: brand stabilization + Tylenol/Listerine recovery + Starboard engagement + post-spin operational reset. Risks: continued brand share losses, activist disruption, post-spin operational challenges extending.